Dietary starch may raise risk of breast cancer recurrence

Share this content:

An increase in carbohydrate intake—particularly starch intake—has been linked with breast cancer recurrence in a study presented at the CTRC-AACR San Antonio Breast Cancer Symposium, held December 6-10, 2011, in San Antonio, Texas.

Jennifer A. Emond, MS, a public health doctoral student at the University of California, San Diego, and colleagues conducted a subset analysis of 2,651 women who participated in the Women's Healthy Eating and Living (WHEL) Dietary Intervention Trial for survivors of breast cancer—a plant-based intervention trial that did not have a carbohydrate goal. Participants were followed for an average of 7 years.

The investigators obtained information on patients' carbohydrate consumption from multiple 24-hour dietary recalls at baseline and at 1 year, and from annual phone interviews in which the women reported everything they had eaten in the preceding 24 hours.

Baseline carbohydrate intake was 233 g/day. Women who experienced a breast cancer recurrence had a mean increase in carbohydrate intake of 2.3 g/day over the first year. By comparison, those who did not have a recurrence had a mean decrease in carbohydrate intake of 2.7 g/day). Change in starch intakes accounted for nearly half (48%) of the change in carbohydrate intake: Mean first-year change in starch intake, which was achieved independent of the study intervention, was –4.1 g/day among women with recurrences and –8.7 g/day among the others.

When starch intake changes during 1 year were grouped into quartiles of change, women who increased their starch intake the most during that period had a recurrence rate of 14.2%, compared with 9.7% among the women who reduced their starch intake the most. In an adjusted model, an increase in starch of 5 g/day related to a 3% increased risk of recurrence. The increased risk was limited to women diagnosed with low-grade tumors.

The results suggest that dietary modifications targeting starch intake should be investigated further as a preventive measure against breast cancer recurrence.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs